Vollständiger Abstract
Worum geht es in dieser Arbeit?
Engineered T-cells have transformed hematooncology, but CAR transgene-bearing T-cell malignancies have emerged as a rare and serious genomic safety signal after CAR-T therapy. Available data support a multistep model in which pre-existing clonal fitness, CAR-T manufacture, vector integration, construct biology and post-infusion selection may contribute to different degrees. We review reported cases of CAR-transgenic T-cell lymphoproliferative neoplasms (CTTLN) and propose practical diagnostic criteria with a proportionate approach to genomic surveillance.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Francis Baumgartner, Michael J. Dickinson, Piers Blombery
- Quelle
- Blood Journal
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 0006-4971, 1528-0020
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Francis Baumgartner, Michael J. Dickinson, Piers Blombery (2026). CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy. Blood Journal. https://doi.org/10.1182/blood.2026033477
Kontext
Themen, Förderung und Nutzung
Lizenzhinweise: Lizenz 1